ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

NBY NovaBay Pharmaceuticals Inc New

0.088
-0.002 (-2.22%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
NovaBay Pharmaceuticals Inc New AMEX:NBY AMEX Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  -0.002 -2.22% 0.088 0.10 0.09 0.0915 1,480,092 00:39:33

NovaBay Pharmaceuticals to Present at the 7th Annual LD Micro Invitational

30/05/2017 11:50am

Business Wire


NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more NovaBay Pharmaceuticals Charts.

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® lid and lash hygiene for the domestic eye care market, announces that management is scheduled to present a corporate overview at the 7th Annual LD Micro Invitational Conference on Tuesday, June 6, 2017, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time). The conference is being held at Luxe Sunset Boulevard Hotel in Los Angeles.

A live webcast and replay will be available on the Investors section of the Company's website at http://novabay.com/investors/events.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for the wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.

Stay informed on NovaBay's progress:Download our Mobile InvestorApp from the Apple Store or Google PlayLike us on FacebookFollow us on TwitterConnect with NovaBay on LinkedInJoin us on Google+Visit NovaBay's Website

NovaBay ContactsFor NovaBay Avenova purchasing information, please contact:Email usCall us: 1-800-890-0329www.Avenova.comorFrom the CompanyThomas J. PaulsonChief Financial Officer510-899-8809Contact TomorInvestor Contact:LHAJody Cain310-691-7100Jcain@lhai.com

1 Year NovaBay Pharmaceuticals Chart

1 Year NovaBay Pharmaceuticals Chart

1 Month NovaBay Pharmaceuticals Chart

1 Month NovaBay Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock